Literature DB >> 22700814

Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers.

Michael Schöll1, Anders Wall, Steinunn Thordardottir, Daniel Ferreira, Nenad Bogdanovic, Bengt Långström, Ove Almkvist, Caroline Graff, Agneta Nordberg.   

Abstract

OBJECTIVE: To investigate the particular pathology of the Arctic APP (APParc) early-onset familial Alzheimer disease (eoFAD) mutation for the first time in vivo with PET in comparison with other eoFAD mutations and sporadic Alzheimer disease (sAD).
METHODS: We examined 2 APParc mutation carriers together with 5 noncarrier siblings cross-sectionally with (11)C-labeled Pittsburgh compound B (PiB) and (18)F-fluorodeoxyglucose (FDG) PET, as well as MRI, CSF biomarkers, and neuropsychological tests. Likewise, we examined 7 patients with sAD, 1 carrier of a presenilin 1 (PSEN1) mutation, 1 carrier of the Swedish APP (APPswe) mutation, and 7 healthy controls (HCs).
RESULTS: Cortical PiB retention was very low in the APParc mutation carriers while cerebral glucose metabolism and CSF levels of Aβ(1-42), total and phosphorylated tau were clearly pathologic. This was in contrast to the PSEN1 and APPswe mutation carriers revealing high PiB retention in the cortex and the striatum in combination with abnormal glucose metabolism and CSF biomarkers, and the patients with sAD who showed typically high cortical PiB retention and pathologic CSF levels as well as decreased glucose metabolism when compared with HCs.
CONCLUSIONS: The lack of fibrillar β-amyloid (Aβ) as visualized by PiB PET in APParc mutation carriers suggests, given the reduced glucose metabolism and levels of Aβ(1-42) in CSF, that other forms of Aβ such as oligomers and protofibrils are important for the pathologic processes leading to clinical Alzheimer disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22700814     DOI: 10.1212/WNL.0b013e31825fdf18

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  64 in total

1.  Potential for misdiagnosis in community-acquired PET scans for dementia.

Authors:  Sheena M Shipley; Meredith C Frederick; Christopher M Filley; Benzi M Kluger
Journal:  Neurol Clin Pract       Date:  2013-08

2.  Cholinergic basal forebrain atrophy predicts amyloid burden in Alzheimer's disease.

Authors:  Stefan Teipel; Helmut Heinsen; Edson Amaro; Lea T Grinberg; Bernd Krause; Michel Grothe
Journal:  Neurobiol Aging       Date:  2013-10-28       Impact factor: 4.673

3.  Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease.

Authors:  Gaël Chételat; Rik Ossenkoppele; Victor L Villemagne; Audrey Perrotin; Brigitte Landeau; Florence Mézenge; William J Jagust; Vincent Dore; Bruce L Miller; Stéphanie Egret; William W Seeley; Wiesje M van der Flier; Renaud La Joie; David Ames; Bart N M van Berckel; Philip Scheltens; Frederik Barkhof; Christopher C Rowe; Colin L Masters; Vincent de La Sayette; Femke Bouwman; Gil D Rabinovici
Journal:  Brain       Date:  2016-06-29       Impact factor: 13.501

Review 4.  Imaging the evolution and pathophysiology of Alzheimer disease.

Authors:  William Jagust
Journal:  Nat Rev Neurosci       Date:  2018-11       Impact factor: 34.870

5.  Frontal cortex and striatal cellular and molecular pathobiology in individuals with Down syndrome with and without dementia.

Authors:  Sylvia E Perez; Jennifer C Miguel; Bin He; Michael Malek-Ahmadi; Eric E Abrahamson; Milos D Ikonomovic; Ira Lott; Eric Doran; Melissa J Alldred; Stephen D Ginsberg; Elliott J Mufson
Journal:  Acta Neuropathol       Date:  2019-02-07       Impact factor: 17.088

Review 6.  Amyloid fibril polymorphism: a challenge for molecular imaging and therapy.

Authors:  M Fändrich; S Nyström; K P R Nilsson; A Böckmann; H LeVine; P Hammarström
Journal:  J Intern Med       Date:  2018-02-19       Impact factor: 8.989

7.  Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study.

Authors:  Marissa D Zwan; Juha O Rinne; Steen G Hasselbalch; Agneta Nordberg; Alberto Lleó; Sanna-Kaisa Herukka; Hilkka Soininen; Ian Law; Justyna M C Bahl; Stephen F Carter; Juan Fortea; Rafael Blesa; Charlotte E Teunissen; Femke H Bouwman; Bart N M van Berckel; Pieter J Visser
Journal:  Neurology       Date:  2015-10-14       Impact factor: 9.910

Review 8.  Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress.

Authors:  Sam Gandy; Steven T DeKosky
Journal:  Annu Rev Med       Date:  2013       Impact factor: 13.739

Review 9.  Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.

Authors:  Ann D Cohen; Gil D Rabinovici; Chester A Mathis; William J Jagust; William E Klunk; Milos D Ikonomovic
Journal:  Adv Pharmacol       Date:  2012

10.  Pittsburgh Compound-B (PiB) binds amyloid β-protein protofibrils.

Authors:  Ghiam Yamin; David B Teplow
Journal:  J Neurochem       Date:  2016-12-12       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.